|17th March 2020||John W. Higuchi||220,000||Open or private purchase||$0.32||$69,542.00|
|31st December 2019||Mahesh V. Patel||40,000||Open or private purchase||$0.38||$15,340.00|
|10th December 2019||Mahesh V. Patel||25,000||Open or private purchase||$0.40||$9,975.00|
|4th December 2019||Mahesh V. Patel||145,000||Exercise of derivative||$0.00|
|4th December 2019||Morgan R Brown||17,250||Open or private sale||$0.41||$7,075.95|
|4th December 2019||Mahesh V. Patel||43,500||Open or private sale||$0.41||$17,835.00|
|4th December 2019||Morgan R Brown||57,500||Exercise of derivative||$0.00|
|26th November 2019||Mahesh V. Patel||1,100||Open or private purchase||$0.43||$469.70|
|26th November 2019||Mahesh V. Patel||21,928||Open or private purchase||$0.43||$9,385.18|
|26th November 2019||Mahesh V. Patel||1,272||Open or private purchase||$0.43||$542.51|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Lipocine, Inc. focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.